Acesion Pharma
Acesion Pharma is a clinical-stage pharmaceutical company based in Frederiksberg, Denmark, developing novel therapies for atrial fibrillation (AF), the most common cardiac arrhythmia. The company pioneers small-molecule SK ion channel inhibition as a differentiated mechanism to treat AF safely and effectively. Its lead program AP31969 entered Phase 2 clinical trials in January 2026, building on earlier work on the cardioversion candidate AP30663. Acesion Pharma is backed by venture investors including Canaan Partners. As a pharmaceutical R&D company it does not currently publish a public developer API, SDK, or API documentation; this profile captures its corporate identity and public web properties in the API Evangelist network.
Acesion Pharma is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Biotechnology, Healthcare, and Life Sciences.
Acesion Pharma’s developer surface includes engineering blog and 3 more developer resources.
Kin Score
Resources
Commercial 1
Pricing, plans, and the legal terms of use
Company 3
The organization behind the API